Observational study to determine the optimal dose of daptomycin based on pharmacokinetic/pharmacodynamic analysis

Yamada, Tomoyuki; Ooi, Yukimasa; Oda, Kazutaka; Shibata, Yuriko; Kawanishi, Fumiko; Suzuki, Kaoru; Nishihara, Masami; Nakano, Takashi; Yoshida, Miyako; Uchida, Takahiro; Katsumata, Takahiro; Ukimura, Akira

doi:10.1016/j.jiac.2019.11.002

Cited by 21 publications

(25 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, a retrospective clinical observational study conducted in a Japanese university hospital demonstrated that DAP C min was a substantial predictor of CPK elevation. 9) In that study, CPK elevation was observed in 4/20 patients with a C min > 19.5 mg/L, which was similar to our results in patients with elevated CPK (median DAP C min = 23.9 mg/L). TDM of DAP might also be beneficial to avoid treatment failure, 17) as multivariate analysis demonstrated that lower C min of DAP (< 3.18 mg/L) was related to poor treatment outcomes.…”

Section: Discussionsupporting

confidence: 90%

See 1 more Smart Citation

Evaluation of Daptomycin-Induced Cellular Membrane Injury in Skeletal Muscle

Yamada

Ishikawa

Ishiguro

et al. 2020

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

Daptomycin, a cyclic lipopeptide antibiotic, has bactericidal activity against Gram-positive organisms and is especially effective against methicillin-resistant Staphylococcus aureus. Although daptomycin causes unique adverse drug reactions such as elevation of creatine phosphokinase or rhabdomyolysis, the detailed mechanisms underlying these adverse drug reactions in skeletal muscle are unclear. This study aimed to elucidate whether daptomycin causes direct skeletal muscle cell toxicity and investigate the relationship between daptomycin exposure and musculoskeletal toxicity. First, we evaluated the relationship between daptomycin exposure and skeletal muscle toxicity. Of the 38 patients who received daptomycin intravenously, an elevation in creatine phosphokinase levels was observed in five. The median plasma trough concentration of daptomycin in patients with elevated creatine phosphokinase levels was significantly higher than that in patients whose creatine phosphokinase levels were within the normal range, suggesting that increased exposure to daptomycin is related to elevation in creatine phosphokinase levels. In an in vitro study using human rhabdomyosarcoma cells, daptomycin reduced cell viability and increased membrane damage. These effects were more marked under hypoxic conditions. A necroptotic pathway seemed to be involved because phosphorylated mixed lineage kinase domain-like protein expression was enhanced following daptomycin exposure, which was significantly enhanced under hypoxic conditions. These findings indicate that daptomycin elicits cytotoxic effects against skeletal muscle cells via the necroptotic pathway, and the extent of toxicity is enhanced under hypoxic conditions.

show abstract

Section: Discussionsupporting

confidence: 90%

“…Recently, another observational study suggested that DAP C min was significantly associated with CPK elevation based on a logistic regression model. 9) The study suggested that frequent CPK monitoring is needed, and therapeutic drug monitoring (TDM) of DAP may be desirable when high-dose DAP is prescribed.…”

Section: Introductionmentioning

confidence: 99%

Evaluation of Daptomycin-Induced Cellular Membrane Injury in Skeletal Muscle

Yamada

Ishikawa

Ishiguro

et al. 2020

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

show abstract

“…Data on sex, age, weight, height and adverse events related to muscle toxicity were collected. Data on statin use, 3 high‐dose daptomycin (>6 mg/kg), 6 and the presence of chronic kidney disease (CKD) 7 and obesity 3 were also collected as potential risks of muscle toxicity for daptomycin therapy. Vancomycin, which is one of the most frequently used drugs to treat MRSA infection, 1 was used as a control drug for daptomycin.…”

Section: Methodsmentioning

confidence: 99%

Risk of muscle toxicity events for daptomycin with and without statins: Analysis of the Japanese Adverse Event Report database

Yamada

Mitsuboshi

Suzuki

et al. 2021

Basic Clin Pharma Tox

Self Cite

View full text Add to dashboard Cite

“…In addition, in order to monitor the risk of toxicity, there is an interest in monitoring daptomycin concentrations for patients receiving high doses. [116] Few (one to our knowledge) commercial kits are available for the determination of daptomycin, but HPLC-UV and LC-MS/MS assay methods have been published (see bioanalytical section). Some targets for efficacy and toxicity have been published.…”

Section: Therapeutic Drug Monitoring (Tdm)mentioning

confidence: 99%

Clinical Pharmacokinetics of Daptomycin

Grégoire¹,

Chauzy²,

Buyck³

et al. 2020

Clin Pharmacokinet

View full text Add to dashboard Cite

Due to the low level of resistance observed with daptomycin, this antibiotic has an important place in the treatment of severe Gram-positive infections. It is the first in class of the group of calcium-dependent, membrane binding lipopeptide. It is a cyclic peptide constituted of 13 amino acids and a n-decanoyl fatty acid chain. The antibacterial action of daptomycin requires its complexation with calcium.Daptomycin is not absorbed from the gastrointestinal tract and needs to be administered parenterally. The distribution of daptomycin is limited (volume of distribution of 0.1 L/kg in healthy volunteers) due to its negative charge at physiological pH and its high binding to plasma proteins (about 90%). Its elimination is mainly renal, with about 50% of the dose excreted unchanged in the urine, justifying dosage adjustment for patients with renal insufficiency. Pharmacokinetics of daptomycin is altered under certain pathophysiological conditions, resulting in high inter-individual variability. As a result, therapeutic drug monitoring (TDM) of daptomycin may be of interest for certain patients such as intensive care unit (ICU) patients, patients with renal or hepatic insufficiency, dialysis patients, obese patients or children. A target for the ratio of the area under the curve to the minimum inhibitory concentration (AUC/MIC) greater than 666 is usually recommended for clinical efficacy, whereas in order to limit the risk of undesirable muscular effects the residual concentration (Cmin) should not exceed 24.3 mg/L.

show abstract

Observational study to determine the optimal dose of daptomycin based on pharmacokinetic/pharmacodynamic analysis

Cited by 21 publications

References 12 publications

Evaluation of Daptomycin-Induced Cellular Membrane Injury in Skeletal Muscle

Evaluation of Daptomycin-Induced Cellular Membrane Injury in Skeletal Muscle

Risk of muscle toxicity events for daptomycin with and without statins: Analysis of the Japanese Adverse Event Report database

Clinical Pharmacokinetics of Daptomycin

Contact Info

Product

Resources

About